Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CD93 maintains endothelial barrier function and limits metastatic dissemination
Kalyani Vemuri, Beatriz de Alves Pereira, Patricia Fuenzalida, Yelin Subashi, Stefano Barbera, Luuk van Hooren, Marie Hedlund, Fredrik Pontén, Cecilia Lindskog, Anna-Karin Olsson, Roberta Lugano, Anna Dimberg
Kalyani Vemuri, Beatriz de Alves Pereira, Patricia Fuenzalida, Yelin Subashi, Stefano Barbera, Luuk van Hooren, Marie Hedlund, Fredrik Pontén, Cecilia Lindskog, Anna-Karin Olsson, Roberta Lugano, Anna Dimberg
View: Text | PDF
Research Article Oncology Vascular biology

CD93 maintains endothelial barrier function and limits metastatic dissemination

  • Text
  • PDF
Abstract

Compromised vascular integrity facilitates extravasation of cancer cells and promotes metastatic dissemination. CD93 has emerged as a target for antiangiogenic therapy, but its importance for vascular integrity in metastatic cancers has not been evaluated. Here, we demonstrate that CD93 participates in maintaining the endothelial barrier and reducing metastatic dissemination. Primary melanoma growth was hampered in CD93–/– mice, but metastatic dissemination was increased and associated with disruption of adherens and tight junctions in tumor endothelial cells and elevated expression of matrix metalloprotease 9 at the metastatic site. CD93 directly interacted with vascular endothelial growth factor receptor 2 (VEGFR2) and its absence led to VEGF-induced hyperphosphorylation of VEGFR2 in endothelial cells. Antagonistic anti-VEGFR2 antibody therapy rescued endothelial barrier function and reduced the metastatic burden in CD93–/– mice to wild-type levels. These findings reveal a key role of CD93 in maintaining vascular integrity, which has implications for pathological angiogenesis and endothelial barrier function in metastatic cancer.

Authors

Kalyani Vemuri, Beatriz de Alves Pereira, Patricia Fuenzalida, Yelin Subashi, Stefano Barbera, Luuk van Hooren, Marie Hedlund, Fredrik Pontén, Cecilia Lindskog, Anna-Karin Olsson, Roberta Lugano, Anna Dimberg

×

Figure 9

VEGFR2 inhibition restores tumor vessel integrity in CD93-deficient mice and reduces metastatic dissemination.

Options: View larger image (or click on image) Download as PowerPoint
VEGFR2 inhibition restores tumor vessel integrity in CD93-deficient mice...
Immunofluorescent staining of VE-cadherin (A), ZO1 (C), and MMP9 (E) in HCmel12 subcutaneous tumors from wild-type and CD93–/– mice treated with DC101 or isotype control (ISO). Scale bars: 20 μm. (B, D, and F) VE-cadherin (B), ZO1 (D), and MMP9 (F) expression was quantified and normalized to the CD31+ area. Wild-type ISO (n = 6–8), CD93–/– ISO (n = 7–9), wild-type DC101 (n = 7–10), and CD93–/– DC101 (n = 4–6). *P < 0.05; **P < 0.01; ****P < 0.0001 by 1-way ANOVA with Tukey’s multiple-comparison test. NS, not significant. All immunofluorescence quantifications were performed in a minimum of 5 fields of view/sample. (G) Percentage of mice that developed lung metastasis after subcutaneous inoculation of HCmel12 cells. Wild-type ISO (n = 10), CD93–/– ISO (n = 9), wild-type DC101 (n = 10), and CD93–/– DC101 (n = 10). (H) Metastatic burden per mouse (percentage of lung tissue area covered by metastases). Wild-type ISO (n = 10), CD93–/– ISO (n = 9), wild-type DC101 (n = 10), and CD93–/– DC101 (n = 10). *P < 0.05, **P ≤ 0.01 by 1-way ANOVA with Tukey’s multiple-comparison test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts